NASDAQ:PRNB
Delisted

Principia Biopharma Stock News

etoro logo Buy PRNB
*Your capital is at risk
$100.05
+0 (+0%)
At Close: May 27, 2022
(Bloomberg Opinion) -- Eddie Yoon took over the Fidelity Select Health Care Fund in 2008, just as the financial crisis ushered in the worst recession since the Great Depression. He outperformed heal
Goldman Sachs Group Inc. lifted its position in Principia Biopharma Inc (NASDAQ:PRNB) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Principia Biopharma (NASDAQ:PRNB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Zacks.com reports. The brokerage presently ha
Alliancebernstein L.P. increased its holdings in shares of Principia Biopharma Inc (NASDAQ:PRNB) by 618.7% during the 4th quarter, according to the company in its most recent 13F filing with the Secur
Man Group plc purchased a new position in Principia Biopharma Inc (NASDAQ:PRNB) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commissi
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zosano Pharma (ZSAN), Principia Biopharma (PRNB) and
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zosano Pharma ( ZSAN – Research Report ), Principia Biopharma ( PRNB – Research Report ) and Nabriv
Franklin Resources Inc. lowered its position in shares of Principia Biopharma Inc (NASDAQ:PRNB) by 18.4% during the fourth quarter, Holdings Channel reports. The fund owned 183,600 shares of the compa
In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Buy rating on Principia Biopharma (PRNB), with a price target of $76.00.
In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Buy rating on Principia Biopharma (PRNB – Research
Principia Biopharma (NASDAQ:PRNB)‘s stock had its “buy” rating restated by investment analysts at Stifel Nicolaus in a research note issued to investors on Thursday, AnalystRatings.com reports.
In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB), with a price target of $76.00.
In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma ( PRNB – Research Report ), with a price target of $76.00 . The company’s shares c
AQR Capital Management LLC acquired a new stake in shares of Principia Biopharma Inc (NASDAQ:PRNB) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Excha
Great West Life Assurance Co. Can purchased a new stake in shares of Principia Biopharma Inc (NASDAQ:PRNB) in the fourth quarter, according to the company in its most recent filing with the SEC. The f
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE